Evaluation of the effect of interferon beta-1b in the treatment of COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20200921048786N1
- Lead Sponsor
- Dezfoul University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
Individuals over 18 years of age whose covid-19 disease has been confirmed by PCR test (PCR specification of the test from the Iranian manufacturer - Pishtaz Teb and performed by molecular method) and clinically severely ill
o2sat below 90% despite receiving oxygen
Severe bilateral pulmonary involvement
Satisfaction to participate in the study
Failure to receive any medication other than the standard protocol approved by the National Corona Therapy
Exclusion Criteria
History of drug allergies to similar compounds
Pregnancy and lactation
Infection with other microbial or viral infections
History of heart disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical efficacy according to clinical response based on blood oxygen saturation. Timepoint: Daily. Method of measurement: Pulse oximetry.;LDH levels. Timepoint: Three times a week. Method of measurement: laboratory test.;Duration of hospitalization. Timepoint: End of treatment. Method of measurement: Patient file.;Mortality rate. Timepoint: Daily. Method of measurement: Patient file.;Changes in liver enzymes. Timepoint: twice a week. Method of measurement: laboratory test.;Clinical efficacy of treatment regimen based on changes in respiratory rate. Timepoint: Daily. Method of measurement: Patient record and clinical examination.
- Secondary Outcome Measures
Name Time Method ung involvement status. Timepoint: Weekly. Method of measurement: Interpretation of CT scan.